enGene Therapeutics (ENGN) news
Recent news
Perceptive Advisors reduces ASND, ENGN, Naut, ABVX in 2Q: 13F
Perceptive Advisors LLC, a hedge fund managed by Joseph Edelman, has disclosed its 13F filings for the first quarter of 2026, revealing several notable changes in its portfolio. Among the most significant adjustments are reductions in holdings of Ascendis Pharma A/S (ASND), enGene Holdings Inc.…
AInvest Wire · Aug 14, 2026Engene Therapeutics - appoints Michael Heffernan as chairman of the board - SEC filing
Engene Therapeutics Inc. has announced the appointment of Michael Heffernan as chairman of its board of directors, according to a recent SEC filing [1]. Heffernan brings extensive experience in the biotechnology and pharmaceutical sectors, having previously held leadership roles at several publicly…
AInvest Wire · Jul 16, 2026Engene: Michael Heffernan assumes chairman role
AInvest Wire · Jul 16, 2026enGene fall 12% to $19.17 after peaking at $43 following SPAC deal
AInvest Wire · Nov 1, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.